Neurocrine Biosciences Inc (NBIX.O): Two-Year Durability Data and a Novel CAH Subtype Case Headline an Incrementally Positive ENDO 2026

Research evidence excerpt

Neurocrine Biosciences Inc (NBIX.O): Two-Year Durability Data and a Novel CAH Subtype Case Headline an Incrementally Positive ENDO 2026

Flash |

15 Jun 2026 22:34:00 ET │ 11 pages

Neurocrine Biosciences Inc (NBIX.O)

Two-Year Durability Data and a Novel CAH Subtype Case Headline an

Incrementally Positive ENDO 2026

CITI'S TAKE Buy / High Risk

Price (15 Jun 26 16:00) US$159.51 NBIX highlighted incrementally positive datasets for Crenessity and Vykat

Target price US$246.00 XR at ENDO 2026, which continue to strengthen the long-term

commercial and clinical narratives. On the Crenessity front, the first-ever Expected share price return 54.2%

retrospective case series in 11-beta-hydroxylase-deficient CAH patients Expected dividend yield 0.0%

demonstrated hormonal reductions and GC dose lowering, potentially Expected total return 54.2%

implying benefits in this second most common form of classic CAH, while Market Cap US$16,039M

two-year adult data from the CAHtalyst OLE showed sustained

cardiometabolic improvements alongside durable GC reductions that

could be viewed favorably amongst both payers and prescribers. Mgmt.

also presented pediatric two-year data, which noted compelling bone age Yigal Nochomovitz, Ph.D.AC

and predicted adult height signals that could strengthen the argument for +1-212-816-1441

early treatment adoption. Finally, Soleno's Vykat XR long-term extension yigal.nochomovitz@citi.com

data confirmed durable and recoverable benefit in Prader-Willi syndrome Joohwan Kim

following a randomized withdrawal period, with three-year comparative +1-212-816-0224

data vs. a real-world natural history cohort further anchoring the joohwan.kim@citi.com

treatment effect and providing validation for NBIX’s Soleno acquisition

Caroline DePaul

(here).

+1-212-816-0211